查詢結果分析
來源資料
相關文獻
- Tolerability Assessment of Maximal Androgen Blockade with 50mg Daily of Bicalutamide and Castration in Patients with Advanced Prostate Cancer
- Morbidity with Contemporary Transrectal Biopsy of the Prostate
- 臺灣地區之前列腺癌
- The Role of Percent Free-Prostate Specific Antigen (PSA) in Patients with Total PSA Levels between 4.0 and 10.0 ng/ml
- Prostatic Carcinoma with Brain Metastasis Presenting as a Tumor Hemorrhage
- 前列腺癌腫瘤標記(PSA)最新應用及發展
- 罹患前列腺癌的危險因子--類胰島素生長因子I(IGF-I)
- Rectal Stenosis: An Unusual Presentation of Prostate Adenocarcinoma
- 前列腺癌
- 協助一位住院的前列腺癌患者及家屬渡過癌末的護理經驗
頁籤選單縮合
題 名 | Tolerability Assessment of Maximal Androgen Blockade with 50mg Daily of Bicalutamide and Castration in Patients with Advanced Prostate Cancer=使用Bicalutamide合併去勢治療完全阻斷雄性素法於進展性前列腺癌病患之經驗並評估其耐受度 |
---|---|
作 者 | 莊正鏗; 朱聖賢; 江仰仁; 吳俊德; 林美秀; 魏翠媛; 林素真; | 書刊名 | 長庚醫學 |
卷 期 | 25:9 2002.09[民91.09] |
頁 次 | 頁577-582 |
分類號 | 416.275 |
關鍵詞 | 前列腺癌; 前列腺; 抗雄性素; 完全阻斷雄性素法; Prostate cancer; Prostate; Antiandrogen; Maximal androgen blockade; |
語 文 | 英文(English) |
中文摘要 | 背景: 雄性素是前列腺癌之重要生成因素。對於進展性前列腺癌病患,使用去勢療法合併抗雄性素是廣為採用的方式。選擇賀爾蒙治療要著眼於疾病的控制,更要注重病患的生活品質,治療花費以及治療副作用。 方法: 對於進展性前列腺癌患使用每日50毫克Bicalutamide合併去勢治療,評估病患對藥物耐受度,以及利用前列腺特異抗原的變化評估是否可以作為疾病進展之指標。 結果: 自1997年12月至1999年6月期間,總共有37位進展性前列腺癌病患收納入此次研究。發生副作用之比率大約百分之27。最常見之副作用為臉部潮紅(5.4%)。85.3%之病患治療有效,其前列腺特異抗原明顯下降,但是前列腺特異抗原的變化與疾病進展並無明顯之相關性。 結論: 每日50毫克Bicalutamide合併去勢療法對於治療進展性前列腺癌有相當的安全與耐受度。 |
英文摘要 | .Background: Androgen is the most important growth factor for the development and growth of prostatic adenocarcinomas. For patients with advanced prostate cancer, hormonal manipulation including castration and antiandrogen therapy is a well-established mode of treatment. The choice of hormonal therapy for prostate cancer depends not only on the desired progression-free and overall survival, but also on the patient’s quality of life, treatment costs, and treatment toxicities. Methods: This was an open, non-comparative trial to determine the tolerability of 50mg bicalutamide (Casodex) in combination with castration; we also investigated whether the prostate-specific antigen (PSA) rates of change at weeks 4 and 12 were indicative of an increased risk of progression. Results: Thirty-seven patients were enrolled in the study from December 1996 to June 1999 in Chang Gung Memorial Hospital, Taoyuan. The overall incidence rate of adverse events was 27%. The most frequent adverse event was hot flushes (5.4%). The rate of overall disease response was 85.3%. No evidence was found for any predictive relationship between serum PSA concentration and risk of progression. Conclusion: The overall results indicate that bicalutamide administered as a 50-mg daily dosage in combination with castration is a well-tolerated therapy for the treatment of patients with advanced prostate cancer. |
本系統中英文摘要資訊取自各篇刊載內容。